Dose-ranging study to evaluate the safety and efficacy of olmesartan medoxomil in children and adolescents with hypertension.

Trial Profile

Dose-ranging study to evaluate the safety and efficacy of olmesartan medoxomil in children and adolescents with hypertension.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Olmesartan medoxomil (Primary)
  • Indications Hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms AESOP
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 12 Apr 2010 Results in children and adolescents aged 6-16 years published in Hypertension.
    • 06 Apr 2010 Actual patient number (362) added as reported by ClinicalTrials.gov.
    • 11 Feb 2010 Based on the results of this study, olmesartan medoxomil was approved in the US for paediatric patients 6-16 years of age.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top